Bactoderm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bactoderm

Quick Facts

Property Description
Active Ingredient Mupirocin (as Mupirocin Calcium)
Form Topical Ointment, Topical Cream
Pharmacological Class Topical Antibacterial Agent (Monoxycarbolic Acid Class)
General Purpose Provides localized defense against susceptible bacteria
Origin Naturally derived from Pseudomonas fluorescens

What Type of Medicine is Bactoderm?

Bactoderm is the commercial brand name for a topical antibacterial agent whose active pharmaceutical ingredient is Mupirocin (present as Mupirocin Calcium). As a specialized antibiotic, it belongs to the unique monoxycarbolic acid class and is available strictly by prescription. Mupirocin is designed exclusively for topical administration to the skin or nasal passages. This prescription-only status is supported by clinical recognition of its targeted role in managing localized issues rather than systemic conditions, confirming its distinct positioning within the pharmacopoeia.

Composition and Unique Origin of Mupirocin

The core of the medicine is Mupirocin, a single-component product distinguished by its unusual origin; it is produced through a fermentation process involving the bacterium Pseudomonas fluorescens. This unique production method gives Mupirocin a chemical structure that differs significantly from older, more widespread antibiotic classes. For external application, it is prepared in two dosage forms: a heavier ointment (often based on polyethylene glycol) and a lighter, water-miscible cream (emollient base). Both vehicles ensure that the active ingredient, Mupirocin Calcium, remains highly concentrated for effective action at the application site.

What is the General Purpose of this Topical Antibacterial Agent?

The general purpose of this medication is to provide a highly concentrated, localized defense against susceptible bacteria on the skin surface. This is achieved because Mupirocin works by uniquely disrupting the bacteria’s internal machinery, specifically by inhibiting bacterial protein synthesis by binding to the isoleucyl-tRNA synthetase enzyme. This targeted action rapidly reduces the localized population of harmful bacteria. Clinically, this mechanism is highly valued as it often allows the drug to maintain effectiveness even when bacteria have developed resistance to common oral antibiotics.

Regulatory References

  1. FDA Drug Label (DailyMed - NIH)

What side effects are possible with Bactoderm?

Possible side effects and safety information

The safety profile of Mupirocin (Bactoderm) is based on classifications from official regulatory documents and is structured around two main categories of documented adverse reactions: localized effects and systemic hypersensitivity.

Adverse Reaction Classification

Side effects are categorized by frequency based on official regulatory standards:

Classification Type of Reaction
Common Localized application site reactions such as burning, stinging, itching (pruritus), and erythema (redness).
Uncommon Generalized allergic reactions and skin sensitization reactions, including contact dermatitis.
Rare Severe systemic allergic reactions categorized as Immune System Disorders, such as angioedema (swelling beneath the skin) and urticaria (hives).

Safety Constraints and Considerations

The official labeling includes specific safety limitations regarding the drug’s composition and patient populations. Mupirocin is contraindicated in individuals with a known hypersensitivity to the active ingredient or any excipients. Furthermore, the product is not suitable for ophthalmic (eye) or internal application, as it is strictly for topical use.

A key consideration for the ointment formulation relates to its excipient, polyethylene glycol (PEG). Regulatory documents advise caution when this PEG-based ointment is applied over large areas of broken skin or open wounds in patients with significantly reduced renal function due to the potential for systemic absorption of PEG. Systemic absorption of the active ingredient itself is generally minimal but is noted to increase when applied to extensive damaged skin surfaces.

Overdose and Emergency Response

The official regulatory profile for Bactoderm (Mupirocin) overdose is structured around a low systemic toxicity profile of the active ingredient. Regulatory documents state that systemic absorption following topical use is minimal, and the toxicity of mupirocin is very low. Overdose manifestations following topical application are not formally documented. Even high oral and intravenous doses of the active ingredient have been formally reported as well tolerated in clinical studies, underscoring the limited systemic risk from Mupirocin itself.

When to Seek Help

Urgent medical attention is required in the event of accidental oral intake of the ointment or cream. The official regulatory response is that no specific treatment or antidote is known for an overdose; therefore, management must consist of symptomatic and supportive treatment and appropriate monitoring.

Population-Specific Monitoring

A key consideration applies to the ointment formulation, which contains the excipient polyethylene glycol. For patients with moderate or severe renal impairment, the erroneous oral intake of large quantities of the ointment requires close monitoring of renal function. This mandated precaution addresses the potential systemic effects of the polyethylene glycol component, and not the antibacterial component itself. In all cases of ingestion, a patient should consult the doctor immediately or a national poisons centre.

Therapeutic Uses of Bactoderm

What Bactoderm Treats: Main Uses and Benefits

This medication is commonly used across conditions presenting with acute episodes of localized bacterial skin disease that create noticeable physiological strain. It is considered relevant for symptomatic management of primary and secondary bacterial skin infections.

The therapeutic scope generally involves superficial infections like impetigo and folliculitis; secondarily infected wounds (cuts and scrapes); and the specialized application of nasal decolonization for carriers of Staphylococcus aureus (including MRSA). This medicine is applied in clinical settings where additional management of discomfort is required due to symptoms related to inflammatory or irritative states, such as localized redness, tenderness, and pus formation.

A main focus is to contribute to improved comfort during periods of heightened symptoms. This application provides support that helps ease the overall symptom burden and assists with maintaining functional stability by addressing the bacterial component.


Quick Fact: Symptom Management Focus Symptom Group Therapeutic Benefit
Crusting and Pustules (Impetigo) Plays a role in managing lesion spread
Localized Redness & Tenderness May assist with easing discomfort and inflammation
Nasal S. aureus Carriage Addresses the management of subsequent infection risk

Eligibility and Restrictions for Use

This section explains the officially documented eligibility and non-eligibility rules for Mupirocin (Bactoderm), based strictly on government regulatory documents.

Contraindications and Absolute Restrictions

Category Restriction Status Official Requirement
Hypersensitivity Contraindicated Must not be used by individuals with a known allergy to mupirocin or any of the excipients in the formulation (e.g., polyethylene glycol).
Application Site Restricted The topical ointment is not suitable for use on mucosal surfaces (eyes, mouth), in conjunction with intravenous cannulae, or at central venous sites.

Age-Specific Eligibility Rules

Age Group Regulatory Status Context
Adults & Adolescents Permitted Fully covered under standard labeled conditions.
Children Permitted Safety and effectiveness are established for children aged 2 months and older (US FDA) or 4 weeks and older (EU/UK SmPC).
Newborns Use Not Recommended Not recommended for infants under 4 weeks of age as safety and effectiveness have not been established.

Conditional Use and Comorbidity Limitations

  • Renal Impairment: The ointment formulation should not be used where absorption of large quantities of the polyethylene glycol base is possible (e.g., over extensive damaged skin), especially if there is evidence of moderate or severe kidney impairment.
  • Pregnancy & Lactation: Use during pregnancy is conditional and should occur only if clearly needed and the benefit outweighs the potential risk. When used on the breast or nipple during lactation, the area must be washed thoroughly prior to breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Bactoderm (Mupirocin) is primarily based on administrative and excipient-driven constraints, reflecting its localized topical use and minimal systemic absorption. Regulatory documents do not report studies for interactions with systemically administered medicinal products.

Interaction-Related Restrictions

Constraint Type Officially Documented Restriction
Pharmacodynamic/Administrative Prohibition on concurrent application with other topical products (creams, lotions, or ointments).
Excipient-Based/Population Restriction on use of the Ointment formulation in patients with moderate or severe renal impairment due to the Polyethylene Glycol (PEG) base.

Officially Documented Interaction Statements

The primary administrative constraint mandates that Mupirocin formulations must not be applied concurrently with any other topical preparation at the application site. This procedural rule is established to prevent the dilution of the active ingredient and potential loss of its stability and antibacterial activity.

For the Ointment form, a population-specific restriction applies because the excipient, Polyethylene Glycol, can be absorbed from damaged skin and is cleared by the kidneys. Regulatory labeling states that the Ointment should not be used when large quantities of PEG could be absorbed in patients with compromised kidney function.

Mechanism of Action

How Bactoderm Works: Mechanism of Action

Bactoderm (mupirocin) exerts its action by interfering selectively with the fundamental biosynthetic processes of susceptible bacteria. Its core mechanism involves the inhibition of the bacterial enzyme isoleucyl-tRNA synthetase (IleRS). This enzyme is crucial for attaching the amino acid isoleucine to its transfer RNA (tRNA), a necessary first step in protein assembly.

By blocking IleRS, the drug immediately halts the formation of new proteins, initiating a multi-faceted mechanistic cascade within the bacterial cell. This metabolic disruption is compounded by a secondary inhibition of bacterial RNA synthesis, leading to a rapid, non-recoverable loss of core metabolic function. This pathway disruption results in a bactericidal effect at the high concentrations achieved locally.

Due to negligible systemic absorption, the drug’s mechanism operates exclusively within the peripheral/topical domain. This confinement ensures the drug’s activity remains highly concentrated at the application site, focusing the physiological consequence of microbial viability collapse to the surface target.

Dosage and Administration Information

Bactoderm (mupirocin) is administered exclusively through localized application, which utilizes either a Topical route for skin use or an Intranasal route for use in the nostrils. The specific 2% formulation must align with the intended area of application, as the topical preparations are not designed for nasal or mucosal use.


Standard Dosing and Frequency

For most skin infections, the Cream or Ointment is applied as a small amount or thin film to the affected area three times daily (TID). The typical course of treatment is limited to 10 days, and a patient's usage should be re-evaluated if a clinical response is not observed within 3 to 5 days.

The Nasal Ointment is administered twice daily (BID), typically morning and evening, for a short and defined duration of 5 days. The dose requires applying approximately one-half of the single-use tube’s contents into each nostril.


Administration and Age Constraints

Administration technique for the nasal product involves a procedural step: the patient must press together and release the sides of the nose repetitively for about one minute after application to ensure the ointment is spread throughout the nares.

The treated skin area may be covered with a sterile gauze dressing if desired. A general constraint is that the formulation must not be mixed with other topical preparations, as this can compromise its stability and efficacy.

Usage is subject to age rules defined by the formulation: the Topical Ointment is used in patients 2 months of age and older, the Cream in patients 3 months of age and older, and the Nasal Ointment in patients 12 years of age and older. If a dose is missed, it should be applied as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Evidence for Use in Primary Bacterial Skin Infections

Research exploring the use of Bactoderm (Mupirocin) relies on short-term Randomized Controlled Trials (RCTs) designed to examine its use in conditions such as impetigo. These trials monitored two main measurements: Clinical Outcome Status (describing how visible signs of the infection changed during the study period) and Bacteriological Status (assessing the presence or absence of the specific bacteria at the study site). Studies report how outcomes related to physical discomfort evolved over defined time intervals, providing context on how the medicine was observed to perform in a clinical trial setting.


Evidence for Nasal Decolonization of S. aureus

The research base for Mupirocin was studied for its use in patients carrying Staphylococcus aureus in the nose, relying on RCTs, often placebo-controlled. Studies explored high-level outcomes such as short-term Bacteriological Status (absence of the target bacteria) and, over longer observation periods, the incidence of subsequent S. aureus infections. Research examined subsequent infection incidence, particularly when Mupirocin was studied alongside other interventions as part of a multi-component strategy.


Evidence in Specific Patient Populations

Bactoderm was evaluated in study populations that included pediatric patients (covering a range from infants upward) with impetigo. Research on nasal decolonization also included older adults undergoing high-risk procedures and critically ill infants. The research indicates that results apply only to the populations studied.


What Research Gaps and Uncertainties Exist

The evidence landscape highlights several areas where certainty remains low. A key limitation is that most regulatory studies have follow-up durations that were limited, making it difficult to fully understand long-term patterns. The potential for the emergence of mupirocin resistance remains an ongoing area of research, with data still emerging on its long-term clinical significance.

Frequently Asked Questions (FAQ)

Common questions about Bactoderm (FAQ)

Q: Is Bactoderm available without a prescription in some places?

Regulatory documents state that in jurisdictions like the US and Canada, Bactoderm (Mupirocin) is available only by prescription. The prescription status in other global regions is determined by local regulatory drug laws.

Q: Is it okay to use Bactoderm if I am pregnant?

Official product information states that the use of this medicine during pregnancy is conditional. It should occur only if it is clearly needed and if a healthcare provider determines that the potential benefit outweighs the potential risk. This guidance respects the limited evidence available regarding its use during pregnancy.

Q: Are there certain age groups who should avoid Bactoderm?

Regulatory labeling establishes specific minimum ages for each formulation. The topical ointment is established for patients 2 months and older, the cream for 3 months and older, and the nasal ointment for patients 12 years and older. The medicine is generally not recommended for infants younger than 4 weeks of age.

Q: What happens if Bactoderm gets in my eye?

The product is strictly for topical use and is not suitable for ophthalmic (eye) application. If accidental contact with the eyes occurs, official patient information indicates that the affected area is typically rinsed with water.

Q: Is there a risk of becoming allergic to Bactoderm?

The drug is contraindicated (absolutely restricted) for use in individuals with a known hypersensitivity or allergy to mupirocin or any of its components. Additionally, localized allergic responses, such as a contact dermatitis skin reaction, are listed as uncommon side effects.

Q: What does it mean if the infection doesn't seem to improve after a few days of using Bactoderm?

Regulatory documents advise that if a patient does not show a clinical response (improvement) within 3 to 5 days of starting treatment, usage and condition are typically re-evaluated by a healthcare provider. This time frame helps determine if the current treatment plan remains appropriate.

Q: Is it necessary to finish the entire course of Bactoderm even if the infection looks gone?

Official guidance indicates that the medication is intended for use for the full course as directed by the prescriber. Completing the entire prescribed duration is described as helping to ensure all infectious bacteria are completely treated and prevent potential recurrence.

Q: Is Bactoderm related to other mupirocin products?

Yes, Bactoderm is the commercial brand name for the active pharmaceutical ingredient Mupirocin (Mupirocin Calcium). All other products containing mupirocin share this same active component, which is the source of the medicine's antibacterial effect.

Q: Does Bactoderm treat fungus or just bacteria?

According to official documents, Bactoderm is classified as an antibiotic, and it is used to treat infections caused by susceptible bacteria. It is important to note that this medicine is not effective against infections caused by fungus or viruses.

Q: Is Bactoderm used for different kinds of skin infections?

Yes, it is indicated for specific types of bacterial skin conditions. The ointment formulation is indicated for conditions like impetigo, while the cream is indicated for secondarily infected traumatic skin lesions (such as cuts or scrapes) caused by susceptible bacteria.

Q: What is the main difference between Bactoderm and a regular topical cream?

Bactoderm is a prescription topical antibacterial agent, while a 'regular' cream may be non-medicinal or contain non-antibiotic ingredients. Bactoderm provides a highly concentrated, localized defense against bacteria due to its unique mechanism of inhibiting bacterial protein synthesis, distinguishing it from general-purpose creams.

Q: Can Bactoderm be used on open cuts or wounds?

Official warnings relate to the polyethylene glycol (PEG) base found in the ointment formulation. This ointment is advised not to be used on large areas of broken skin, open wounds, or burns in patients with significantly reduced kidney function due to the potential for PEG absorption.

Q: Is Bactoderm available in different strengths?

Regulatory documents refer to the 2% formulation as the basis for the topical ointment, cream, and nasal ointment. This indicates that a single concentration of the active ingredient, Mupirocin, is used across the various approved forms.

Q: Does Bactoderm treat staph infections, including MRSA?

Mupirocin has been shown to be active against most strains of Staphylococcus aureus, often called staph infections. Official research also includes its use for the nasal decolonization of S. aureus, including Methicillin-resistant S. aureus (MRSA) strains.

Q: What are the signs of a serious reaction to Bactoderm?

Signs of rare, serious systemic reactions, classified as immune system disorders, can include angioedema (swelling beneath the skin) and urticaria (hives). Patient information often translates these into signs like difficulty breathing, or the swelling of the face, lips, mouth, or throat.

Q: Can using Bactoderm too long cause long-term skin problems?

Official warnings state that, as with other antibacterial products, prolonged or excessively extended use may result in the overgrowth of non-susceptible organisms, which includes certain types of fungi. This emphasizes the importance of using the drug only for the prescribed duration.

Q: Does using a strong soap interact with Bactoderm?

While the primary interaction warning covers other topical medicines, derived patient information is generally described as being best used without strong soaps, abrasive cleansers, or cosmetics on the skin area being treated with Bactoderm.

Q: Are there any internal medicines that interact with Bactoderm?

Due to its localized topical use and minimal systemic absorption, regulatory documents note that studies for interactions with systemically administered (internal) medicines have generally not been reported.

Q: Is there a problem using Bactoderm with steroid creams?

The administrative restriction states that Mupirocin formulations must not be applied concurrently or mixed with any other topical preparations. This procedural rule applies to all other topical products, including steroid creams, applied at the same application site.

Q: Does alcohol consumption affect how Bactoderm works?

There are no reported studies detailing a direct interaction between alcohol consumption and Bactoderm's topical use. However, some clinical studies exclude patients who consume excessive amounts of alcohol due to factors that may compromise treatment compliance or affect study outcomes.

Q: Can I apply makeup over Bactoderm?

Patient information advises that cosmetics or skin care products are generally not applied on the treated skin. This guidance is consistent with the general prohibition against mixing or concurrently applying other topical products.

Q: How fast should I expect to see improvement after starting Bactoderm?

Generally, symptoms are expected to show improvement within 3 to 5 days of starting treatment. This aligns with the window of time used in regulatory guidance to determine if a lack of response warrants a re-evaluation by a healthcare provider.

Q: Can the infection come back after stopping Bactoderm?

Completing the entire prescribed course is described as helping to prevent the recurrence or return of the initial infection. This practice ensures all infectious bacteria are adequately cleared.

Q: How long does the effect of one application of Bactoderm last on the skin?

The recommended dosing frequency is based on the time required to maintain the necessary effective drug concentration. For topical use, this frequency is three times daily (TID), and for nasal use, it is twice daily (BID).

Q: Is Bactoderm the same drug as Polysporin?

Bactoderm (Mupirocin) is not the same drug as Polysporin. Bactoderm is a single-ingredient topical antibiotic, while Polysporin is a combination product containing the active ingredients bacitracin and polymyxin B.

Q: Why do some doctors prescribe Bactoderm over oral antibiotics?

The drug is designed to provide direct, high-concentration antimicrobial activity precisely at the infection site, which limits systemic exposure. Furthermore, it has a unique mechanism of action that is often effective even when bacteria have developed resistance to certain common oral antibiotics.

Q: Can Bactoderm be used for acne breakouts?

Official product information shows that Mupirocin does not have FDA approval as a treatment option for acne. Its approved indications are specific primary and secondary bacterial skin infections, as well as nasal decolonization.

How should Bactoderm be stored and disposed of?

How to Store and Dispose of Bactoderm (Mupirocin)

The storage and disposal of Bactoderm must follow the conditions specified in official regulatory labeling to ensure product integrity and safety.


Storage Requirements

Mupirocin must be stored at Controlled Room Temperature (CRT), typically 20 C to 25 C (68 F to 77 F). The product must not be frozen and should be protected from excessive heat. It is mandatory to store the medication out of the sight and reach of children and to keep the container seal intact prior to first use. Some labels specify an in-use stability period, requiring the contents to be discarded within 10 days after first opening or upon completion of treatment.


Disposal Instructions

Any unused or expired product, along with the waste material, must be disposed of in accordance with local requirements. This ensures the medicine is handled as pharmaceutical waste and is not placed into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bactoderm found in:

A-Z Index: